WO2014123375A1 - 총경동맥 또는 상시상 정맥동에 출혈이 유발된 지혈제 성능평가 동물모델 및 그 용도 - Google Patents
총경동맥 또는 상시상 정맥동에 출혈이 유발된 지혈제 성능평가 동물모델 및 그 용도 Download PDFInfo
- Publication number
- WO2014123375A1 WO2014123375A1 PCT/KR2014/001034 KR2014001034W WO2014123375A1 WO 2014123375 A1 WO2014123375 A1 WO 2014123375A1 KR 2014001034 W KR2014001034 W KR 2014001034W WO 2014123375 A1 WO2014123375 A1 WO 2014123375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemostatic
- animal model
- bleeding
- efficacy
- animal
- Prior art date
Links
- 238000010171 animal model Methods 0.000 title claims abstract description 81
- 229940030225 antihemorrhagics Drugs 0.000 title claims abstract description 52
- 239000002874 hemostatic agent Substances 0.000 title claims abstract description 52
- 210000001168 carotid artery common Anatomy 0.000 title claims abstract description 39
- 210000000798 superior sagittal sinus Anatomy 0.000 title claims abstract description 15
- 208000032843 Hemorrhage Diseases 0.000 title abstract description 61
- 230000001939 inductive effect Effects 0.000 title abstract description 7
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 60
- 238000011156 evaluation Methods 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000012216 screening Methods 0.000 claims abstract description 10
- 230000000740 bleeding effect Effects 0.000 claims description 63
- 241001465754 Metazoa Species 0.000 claims description 27
- 230000023597 hemostasis Effects 0.000 claims description 18
- 210000002808 connective tissue Anatomy 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 4
- 229920000742 Cotton Polymers 0.000 description 18
- 206010002091 Anaesthesia Diseases 0.000 description 12
- 230000037005 anaesthesia Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003625 skull Anatomy 0.000 description 6
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 5
- 229940064804 betadine Drugs 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 229960001929 meloxicam Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003106 tissue adhesive Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960003408 cefazolin sodium Drugs 0.000 description 2
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000003894 surgical glue Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical class OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- PFSVSOOFNDBGMO-UHFFFAOYSA-N 3-methoxypropyl 2-cyanoprop-2-enoate Chemical class COCCCOC(=O)C(=C)C#N PFSVSOOFNDBGMO-UHFFFAOYSA-N 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- -1 alkyl 2-cyanoacryloyl glycolates Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Definitions
- the present invention relates to an animal model for evaluating hemostatic performance and its use, and more particularly, to a hemostatic agent that causes bleeding in an animal's common carotid artery (CCA) or superior sagittal sinus (SSS). Performance Evaluation
- CCA common carotid artery
- SSS superior sagittal sinus
- the present invention relates to an animal model, a method for screening a hemostatic agent using the animal model, and a method for evaluating a hemostatic effect.
- Medical instant adhesive in the broad sense includes adhesives such as band-aids, packaging for medical devices, surgical adhesives and hemostatic agents, and in the narrow sense, directly used in medical fields such as skin, blood vessels, digestive organs, and plastic surgery. Means adhesive. Therefore, the medical instant adhesive is in contact with the skin, so biocompatibility is required, there should be no toxicity and risk in vivo, biodegradable and hemostatic effect, instant adhesion can be terminated even in the presence of moisture, and the healing of the living body Should not be disturbed.
- Medical adhesive materials currently in use include cyanoacrylates, fibrin glues, gelatin glues, and polyurethanes. Closure Medical of the United States commercialized a medical tissue adhesive of octylcyanoacrylate called Dermabond in 1997. In August, the company obtained approval from the European Community, followed by approval by the US FDA in 1998. Ethicon, a subsidiary of Johnson & Johnson, has a monopoly on the product, which has been sold simultaneously in 50 countries, including the United States, Europe, and Japan, and is used to seal the incisional skin after laceration, plastic surgery, and reconstructive surgery worldwide. The scope of application is expanding to medical use.
- tissue adhesive research using 1,2-isopropylideneglyceryl 2-cyanoacrylates, alkyl 2-cyanoacryloyl glycolates and methoxypropyl cyanoacrylates containing poly (trioxyethyleneoxalate) has been actively conducted in consideration of biocompatibility and biodegradability.
- fibrin which is an adhesive material
- researchers have been applying bioactive materials of protease substrates and peptides for ligands that can bind to specific cells to fibrin.
- Cohesion of the United States has developed and applied CoStasis TM, a fibrin-collagen composite tissue adhesive containing thrombin and bovine collagen combined with the patient's own plasma, as a hemostatic agent.
- the US FDA approved a surgical glue, Tissel, for the first time in cardiac bypass surgery, colorectal surgery, trauma, and many other products are awaiting FDA approval.
- the present inventors have continued to develop a new and effective animal model for evaluating hemostatic performance and a method for evaluating the efficacy of hemostatic agents using the same, and as a result, the common carotid artery (CCA) or the superior sagittal sinus of animals (SSS)) to produce a bleeding-induced animal model, by confirming that the animal model is useful for testing the efficacy of hemostatic agents, the present invention was completed.
- CCA common carotid artery
- SSS superior sagittal sinus of animals
- An object of the present invention to provide an animal model for hemostatic performance evaluation.
- Another object of the present invention to provide a method of screening a hemostatic agent using the animal model.
- Still another object of the present invention is to provide a method for evaluating the efficacy of a hemostatic agent using the animal model.
- the present invention is a hemostatic agent that is induced bleeding in the common carotid artery (CCA) or a hemostatic agent in which bleeding is induced in the animal model or superior sagittal sinus (SSS) Provide an animal model for performance evaluation.
- CCA common carotid artery
- SSS superior sagittal sinus
- the present invention also provides a method for screening a hemostatic agent from a hemostatic agent using the hemostatic agent evaluation animal model.
- the present invention also provides a method for evaluating the efficacy of a hemostatic agent using the hemostatic agent performance evaluation animal model.
- 1 is a view showing the anesthesia step of the experimental animal.
- FIG. 2 is a view showing a state in which an area to be treated is removed after anesthesia of an experimental animal, and a head is fixed to a experimental table.
- Figure 3 is a diagram showing the step of applying a temperature sensor to the anus after lubricating the temperature sensor, grabbing the tail of the experimental animal.
- Figure 4 is a view showing the removal of the connective tissue incision in the surgical site of the artery model, to reveal the artery.
- FIG. 5 is a diagram illustrating a common carotid artery (CCA) that is a surgical site of an artery model.
- CCA common carotid artery
- FIG. 6 is a view showing that the hemostatic agent is applied to the cotton for hemostasis after induction of bleeding.
- FIG. 7 is a view showing the incision of the scalp of the head in the vein model.
- Fig. 8 is a diagram showing the location of the superior sagittal sinus (SSS) by securing the procedure site by dissecting the skull.
- SSS superior sagittal sinus
- FIG. 9 is a view showing the hemostatic efficacy test results of the hemostatic agent using an arterial animal model.
- FIG. 10 is a view showing the hemostatic efficacy test results of the hemostatic agent candidate material using a vein animal model.
- the present invention relates to an animal model for evaluating hemostatic agent efficacy in which bleeding is induced in the common carotid artery (CCA) and the superior sagittal sinus (SSS) of an animal.
- CCA common carotid artery
- SSS superior sagittal sinus
- the animal model for hemostatic efficacy evaluation according to the present invention can be produced through the following steps: (a) securing the arterial site of the animal; And (b) causing bleeding in the common carotid artery (CCA) of the animal.
- CCA common carotid artery
- the animal model for evaluation of hemostatic efficacy according to the present invention may be prepared by the following steps: (a ') securing an intravenous site of the animal; And (b ') causing bleeding in the permanent sagittal sinus (SSS) of the animal.
- SSS permanent sagittal sinus
- step (a) it may further comprise the step of anesthetizing the experimental animal.
- Such anesthesia may be performed according to a method commonly performed by those skilled in the art, and the method is not limited thereto, but anesthesia may be performed by administering zoletil / rumoon (Zoletil / Rompun); Anesthesia by administering ketamine / xylazine / acepromazine; Anesthesia by administration of sodium pentobarbital alone; Or it is preferable to use a method of anesthesia using isoflurane (isoflurane).
- the anesthesia may be performed by maintaining Zoletil / Rompun, administering sap (Lactated Ringer's solution, etc.) during surgery, and administering antibiotics and analgesics after surgery.
- sap Lacated Ringer's solution, etc.
- Experimental animals in the steps (a) and (a ') may include any animal capable of causing bleeding, preferably mammals, more preferably mice, guinea pigs, hamsters, rats, rodents, cats, dogs And non-human primates such as pigs, rabbits, sheep, goats, deer, horses, cattle, baboons, chimpanzees and monkeys.
- the total carotid artery and the permanent venous sinus in the steps (b) and (b ') are characterized by having local characteristics independent of the experimental animals.
- animals can use rodents of 7-15 weeks of age, preferably rats, and more preferably use 10-week-old, 350-500 g individuals.
- the artery has a large amount of blood (bleeding bleed), which is a criterion for quantifying the bleeding time and site
- the vein is a standard for standardizing a skull incision and selecting a vein.
- the common carotid artery is a carotid artery that supplies blood to the brain and head in the heart, and has a characteristic that blood is ejected upon injury, and thus, the common carotid artery (CCA)
- an effective animal model can be constructed to test the efficacy of the hemostatic agent.
- CCA common carotid artery
- the animal is anesthetized and fixed, and then the area of the procedure is disinfected with hair removal and betadine, and after cutting the midline of the neck from the midline of the rat about 1-5 cm (scissors), it is combined with a cotton swab. It is desirable to remove the tissues, and more preferably incise 3-4 cm from the midline to the neck.
- CCA common carotid artery
- the common carotid artery (CCA) is stabbed at a certain angle with a needle of 10-40G, causing damage and inducing bleeding. At this time, it is preferable to incline the angle with a syringe of 31G to induce bleeding.
- the superior sagittal sinus (SSS) is difficult to spontaneous hemostasis at the time of injury, and is easy to cause side effects such as occlusion, and thus, when bleeding is induced, an effective animal that can test the efficacy of the hemostatic agent You can build a model.
- the exposed vein is injured using a 10-40G surgical knife to induce bleeding.
- the animal model in which bleeding is induced in the common carotid artery (CCA) or the superior sagittal sinus (SSS) according to the present invention evaluates the efficacy of the hemostatic agent candidate or the hemostatic agent from the hemostatic agent candidate. Can be used for screening.
- CCA common carotid artery
- SSS superior sagittal sinus
- a hemostatic agent After bleeding is induced, it is preferable to apply 0.1-1 ml of a hemostatic agent to the bleeding site at the site of bleeding in the superior sagittal sinus (SSS), and then check for hemostasis in 2 minutes. .
- SSS superior sagittal sinus
- the hemostatic agent candidate is preferably suspended in a solvent and then used in the surgical site of the animal model.
- the present invention relates to a method for screening a hemostatic agent from a hemostatic agent using a hemostatic performance evaluation animal model.
- the present invention relates to a method for evaluating the efficacy of a hemostatic agent using an animal model for hemostatic performance evaluation.
- Animals used in this example are about 350-450 g at 10 weeks old SD / Rat.
- the area to be treated is depilated widely, fixed to the experimental table (Stereotaxic frame) (figure 2), and a constant temperature thermometer of the warm pad (warm pad) is inserted into and fixed to the anus of the rat (figure 3), After sterilizing betadine on the epilator of the animal, incision about 3-4 cm from the midline of the neck to the neck of the rat, and then removing the connective tissue with a cotton swab, as shown in FIG. , The muscles (Omohyoid muscle) passing through the upper vessel is cut with a cotton swab (Fig. 4).
- CCA common carotid artery
- Animals used in this example are about 350-450 g at 10 weeks old SD / Rat.
- the area to be treated is depilated widely, fixed to the experimental table (Stereotaxic frame) (figure 2), and a thermometer of a warm pad (warm pad) is inserted into and fixed to the anus of the rat to maintain a constant body temperature (figure 3), After disinfecting betadine on the epilated part of the animal, incision about 2 ⁇ 3 cm from the center of the eye to the part with the ear using a scalpel (No. 10), open the incision and secure it with forceps. , Using a cotton swab to remove the connective tissue and exposed the skull (Fig. 7).
- the centers of the lambda and bregma of the skull are now ground about 5 mm using a diamond grinder. Grind as thin as possible, grind slightly with a sharp forceps or scalpel, expose the bones, and then place the 20 G surgical knife (the beveled side up) in the Superior Sagittal Sinus (SSS) (center of Lambda and Bregma). Induction of bleeding to prepare a hemostatic efficacy evaluation animal model.
- SSS Superior Sagittal Sinus
- Hemostatic efficacy evaluation To prepare an animal model, the procedure was started 20 minutes after anesthesia by subcutaneous injection of 0.5 ml / kg (5 zoletil 5 ml + 2.5 ml lump) into the hind leg muscle of the rabbit.
- Animals used in this example is New Zealand White rabbit about 2.3 ⁇ 3.0 kg.
- the area to be treated was depilated widely, local anesthesia with lidocaine, and fixed on the operating table with hyperhypo thermia.
- Hemostatic efficacy evaluation To prepare an animal model, the procedure was started 20 minutes after anesthesia by subcutaneous injection of 0.5 ml / kg (5 zoletil 5 ml + 2.5 ml lump) into the hind leg muscle of the rabbit.
- Animals used in this example is New Zealand White rabbit about 2.3 ⁇ 3.0 kg.
- the area to be treated was depilated widely and fixed on an operating table on which hyperhypo thermia was installed.
- 0.4 mL of the Heparin sodium (25,000 I.U./5 mL) stock solution was mixed with 3.6 mL of water for injection (THF), 0.4 mL of this solution was injected, and the surgical site was disinfected with betadine.
- An animal model was prepared by exposing the femoral artery while cutting the fascia and muscle within 15 minutes, exposing the femoral artery and inducing bleeding with a 23 G needle on the exposed femoral artery after 15 minutes.
- the bleeding site was pressed by using a cotton, or by pressing the hemostatic agent on the cotton was pressed from the side rather than from the top to prevent the airway from being pressed.
- Example 1 the animal models prepared in Example 1 were divided into 4 groups (5 / group) to evaluate the hemostatic performances of the hemostatic candidates InnoSEAL TM-2 and InnoSEAL TM-3 .
- the subject for the stability evaluation of the animal model was monitored for two weeks, and whether survival, weight, etc. were observed.
- Example 1 the animal models prepared in Example 1 were divided into 4 groups (per 3 / group) to evaluate the hemostatic efficacy of hemostatic agents InnoSEAL TM-2 and InnoSEAL TM-3 .
- InnoSEAL TM-3 showed a hemostatic efficacy similar to the commercial Floseal (Postive control). In FIG. 10, a negative control is not treated.
- the animals were monitored for two weeks, and the survival and weight increase and decrease were observed, and euthanized when the experiment was finished.
- the hemostatic candidate material suspended in an appropriate solvent was applied to the hemorrhagic region of the animal model in which hemorrhage was induced in the liver tissue prepared in Example 3.
- the anti-bleeding composition was applied and hemostasis within 4 minutes was evaluated by the eyes of the experimenter.
- Group 1 was not treated as a negative control, and Group 2 was treated with Floseal ® (Baxter) to cover the bleeding area as a positive control. .
- Experiment 3 (Group 3) was coated with InnoSEAL hydrogel to cover all the bleeding area.
- Experimental groups 2 and 3 additionally applied up to 4ml of the bleeding suppression composition when the amount of bleeding was large.
- Group 4 placed up to two InnoSEAL sponges on the liver in such a way as to cover the bleeding area. InnoSEAL hydrogel was removed after 4 minutes and InnoSEAL sponge was removed after 4 minutes, and hemostasis was evaluated.
- the rabbit was sutured to the treatment area, injected with 0.5 mL Meloxicam (analgesic agent; Meloxicam, Boehringer Ingelheim), and 0.4 mL Cefazolin sodium (antibiotic; Chong Kun Dang) and checked for survival for 24 hours.
- Meloxicam analgesic agent; Meloxicam, Boehringer Ingelheim
- Cefazolin sodium antibiotic; Chong Kun Dang
- InnoSEAL sponge in particular, achieved a hemostasis rate of 100% within 4 minutes, which was very effective in bleeding liver tissue.
- Table 1 Groups Object number Hemostatic Time Hemostasis in 4 minutes Group 1 One 7 minutes 30 seconds 0% 2 8 minutes 30 seconds 3 7 minutes 00 seconds 4 More than 10 minutes 5 6 minutes 30 seconds Group 2 One 5 minutes 00 seconds 40% 2 3 minutes 00 seconds 3 5 minutes 00 seconds 4 5 minutes 00 seconds 5 3 minutes 00 seconds Group 3 One 5 minutes 00 seconds 60% 2 More than 10 minutes 3 4 minutes 00 seconds 4 4 minutes 00 seconds 5 4 minutes 00 seconds Group 4 One 3 minutes 00 seconds 100% 2 4 minutes 00 seconds 3 4 minutes 00 seconds 4 3 minutes 00 seconds 5 3 minutes 00 seconds 5 3 minutes 00 seconds
- the hemostatic candidate material suspended in an appropriate solvent was applied to the bleeding site of the animal model in which hemorrhage was produced in the liver tissue prepared in Example 4.
- Experimental group 1 (Negative control) was treated as a negative control to cover the bleeding area with no treatment and hemostasis by applying a constant pressure
- Experimental group 2 (Group 2) as a positive control Floseal ® (Positive control) Baxter) 1 mL of cotton was applied to the bleeding area and hemostatically under constant pressure.
- Group 3 (Group 3) was coated with 1 mL of InnoSEAL hydrogel to cover the bleeding area and hemostatically under constant pressure.
- Experimental group 4 (Group 4) was hemostatically covered with two cotton pads with InnoSEAL sponge on the bleeding area and applying a constant pressure.
- the cotton was carefully removed at 1 minute 30 seconds, 2 minutes 30 seconds, 3 minutes 30 seconds, 5 minutes, and 7 minutes during the hemostasis and evaluated for hemostasis by the eyes of the experimenter.
- the evaluated animals were analgesic (Meloxicam).
- antibiotics Sephamedin, Cefazolin_sodium
- the animal model according to the present invention can observe the effect of the hemostatic agent quickly and accurately without side effects, and is useful for screening and evaluating efficacy of the hemostatic agent.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Groups | 개체 번호 | 지혈시간 | 4분 내 지혈 달성도 |
Group 1 | 1 | 7분 30초 | 0% |
2 | 8분 30초 | ||
3 | 7분 00초 | ||
4 | 10분 이상 | ||
5 | 6분 30초 | ||
Group 2 | 1 | 5분 00초 | 40% |
2 | 3분 00초 | ||
3 | 5분 00초 | ||
4 | 5분 00초 | ||
5 | 3분 00초 | ||
Group 3 | 1 | 5분 00초 | 60% |
2 | 10분 이상 | ||
3 | 4분 00초 | ||
4 | 4분 00초 | ||
5 | 4분 00초 | ||
Group 4 | 1 | 3분 00초 | 100% |
2 | 4분 00초 | ||
3 | 4분 00초 | ||
4 | 3분 00초 | ||
5 | 3분 00초 |
Groups | 개체 번호 | 지혈시간 | 1분 30초 내 지혈 달성도 |
Group 1 | 1 | 7분 00초 | 0% |
2 | 5분 00초 | ||
3 | 7분 00초 | ||
4 | 7분 00초 | ||
5 | 5분 00초 | ||
Group 2 | 1 | 2분 30초 | 0% |
2 | 2분 30초 | ||
3 | 2분 30초 | ||
4 | 3분 30초 | ||
5 | 2분 30초 | ||
Group 3 | 1 | 2분 30초 | 20% |
2 | 1분 30초 | ||
3 | 3분 30초 | ||
4 | 2분 30초 | ||
5 | 2분 30초 | ||
Group 4 | 1 | 1분 30초 | 80% |
2 | 2분 30초 | ||
3 | 1분 30초 | ||
4 | 1분 30초 | ||
5 | 1분 30초 |
Claims (13)
- 총경동맥(Common Carotid Artery (CCA))에 출혈이 유발되어 있는 지혈 효능평가용 동물모델.
- 제 1항에 있어서, 상기 지혈 효능평가용 동물모델은 다음 단계를 통해 제조된 것임을 특징으로 하는 지혈 효능평가용 동물모델: (a) 동물의 동맥 시술 부위를 확보하는 단계; 및 (b) 상기 동물의 총경동맥(Common Carotid Artery (CCA))에 출혈을 유발시키는 단계.
- 제 2항에 있어서, 상기 동물은 래트인 것을 특징으로 하는 지혈 효능평가용 동물모델.
- 제 2항에 있어서, 상기 (b) 단계는 시술부위를 확보하기 위하여 혈관 주위의 결합조직을 제거한 다음, 주사기를 이용하여 총경동맥(Common Carotid Artery (CCA))에 출혈을 유도하는 것을 특징으로 하는 지혈 효능평가용 동물모델.
- 상시상 정맥동(Superior Sagittal Sinus (SSS))에 출혈이 유발되어 있는 지혈 효능평가용 동물모델.
- 제 5항에 있어서, 상기 동물모델은 다음 단계를 통해 제조된 것임을 특징으로 하는 지혈 효능평가용 동물모델: (a) 동물의 정맥 시술 부위를 확보하는 단계; 및 (b) 상기 동물의 상시상 정맥동(Superior Sagittal Sinus (SSS))에 출혈을 유발시키는 단계.
- 제 6항에 있어서, 상기 동물은 래트인 것을 특징으로 하는 지혈 효능평가용 동물모델.
- 제 6항에 있어서, 상기 (b) 단계는 20G 의료용 칼을 이용하여 동물의 상시상 정맥동 (Superior Sagittal Sinus (SSS))에 손상을 가하여 출혈을 유도시키는 것을 특징으로 하는 지혈 효능평가용 동물모델.
- 제1항 내지 제4항 중 어느 한 항의 지혈 효능평가용 동물모델을 이용하는 것을 특징으로 하는 지혈제 후보물질로부터 지혈제를 스크리닝하는 방법.
- 제 9항에 있어서, 상기 지혈 효능평가용 동물모델의 출혈 부위에 지혈제 후보물질를 도포한 다음 지혈 압박 후, 지혈여부를 확인하는 것을 특징으로 하는 방법.
- 제 5항 내지 제8항 중 어느 한 항의 지혈 효능평가 동물모델을 이용하는 것을 특징으로 하는 지혈제 후보물질로부터 지혈제를 스크리닝하는 방법.
- 제 11항에 있어서, 상기 지혈 효능평가용 동물모델의 출혈 부위에 지혈제 후보물질를 도포한 다음, 지혈여부를 확인하는 것을 특징으로 하는 방법.
- 제 1항 내지 제8항 중 어느 한 항의 지혈 효능평가 동물모델을 이용한 지혈제의 효능 평가방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480007732.1A CN104968197A (zh) | 2013-02-06 | 2014-02-06 | 针对颈总动脉或上矢状窦中诱发出血的止血剂性能评价用动物模型及其用途 |
US14/763,809 US20150359207A1 (en) | 2013-02-06 | 2014-02-06 | Animal model for evaluating performance of hemostatic agent for inducing hemorrhage in common carotid artery or superior sagittal sinus, and use thereof |
EP14748526.2A EP2954778A4 (en) | 2013-02-06 | 2014-02-06 | ANIMAL MODEL FOR EVALUATING THE PERFORMANCE OF A HEMOSTATIC AGENT FOR INDUCING HEMORRHAGE AT THE COMMON CAROTID ARTERY OR SINUS SAGITTAL TOP, AND USE THEREOF |
JP2015555927A JP2016513952A (ja) | 2013-02-06 | 2014-02-06 | 総頚動脈または上矢状静脈洞に出血が誘発された止血剤性能評価動物モデル及びその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130013557A KR101432276B1 (ko) | 2013-02-06 | 2013-02-06 | 총경동맥 또는 상시상 정맥동에 출혈이 유발된 지혈제 성능평가 동물모델 및 그 용도 |
KR10-2013-0013557 | 2013-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014123375A1 true WO2014123375A1 (ko) | 2014-08-14 |
Family
ID=51299920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/001034 WO2014123375A1 (ko) | 2013-02-06 | 2014-02-06 | 총경동맥 또는 상시상 정맥동에 출혈이 유발된 지혈제 성능평가 동물모델 및 그 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20150359207A1 (ko) |
EP (1) | EP2954778A4 (ko) |
JP (1) | JP2016513952A (ko) |
KR (1) | KR101432276B1 (ko) |
CN (1) | CN104968197A (ko) |
WO (1) | WO2014123375A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11885735B2 (en) | 2019-09-13 | 2024-01-30 | Ethicon, Inc. | Ex vivo and in vivo systems for evaluating hemostatic patches, sealants, adhesives on solid organs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002369874A (ja) * | 2001-06-14 | 2002-12-24 | Terumo Corp | 止血材料 |
JP2007181413A (ja) * | 2006-01-05 | 2007-07-19 | Fujifilm Corp | 血管壁障害モデル動物の作成方法 |
KR20070117589A (ko) * | 2005-02-15 | 2007-12-12 | 버지니아 커먼웰스 유니버시티 | 급성 지혈 및 급성 상처와 만성 궤양의 치료를 위한 광물기술 |
KR20080007380A (ko) * | 2005-04-25 | 2008-01-18 | 메사추세츠 인스티튜트 오브 테크놀로지 | 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및방법 |
JP2011518592A (ja) * | 2008-04-25 | 2011-06-30 | メッドトレイド プロダクツ リミテッド | 止血材 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472620A (zh) * | 2006-04-25 | 2009-07-01 | 麻省理工学院 | 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法 |
CN101347624A (zh) * | 2008-06-13 | 2009-01-21 | 上海师范大学 | 一种糖尿病皮肤溃疡动物模型的构建方法 |
CN102067828B (zh) * | 2009-11-24 | 2013-07-10 | 上海市肿瘤研究所 | 人黑色素瘤高转移模型、细胞亚系以及建立方法和转移的动态检测 |
WO2011084326A2 (en) * | 2009-12-21 | 2011-07-14 | Resodyn Corporation | Hemostatic agents and wound dressings |
JP5545853B2 (ja) * | 2010-08-20 | 2014-07-09 | アルパイン株式会社 | 通信装置 |
CN102640725A (zh) * | 2011-02-17 | 2012-08-22 | 浙江中医药大学 | 一种高血压并发高脂血症大鼠模型的制备方法 |
CN102895246A (zh) * | 2011-07-27 | 2013-01-30 | 中国科学院生物物理研究所 | 一种提高体内糖化水平痴呆动物模型的制备方法 |
CN102512259A (zh) * | 2011-11-18 | 2012-06-27 | 新乡医学院 | 一种建立血管性痴呆大鼠模型的新型方法 |
JP2013135704A (ja) * | 2011-12-28 | 2013-07-11 | Hogi Medical:Kk | 止血材及びその製造方法 |
CN102864172B (zh) * | 2012-10-15 | 2014-11-05 | 中国人民解放军第二军医大学 | 基因共转染技术建立的白血病小鼠模型及其制备方法 |
-
2013
- 2013-02-06 KR KR1020130013557A patent/KR101432276B1/ko active IP Right Grant
-
2014
- 2014-02-06 WO PCT/KR2014/001034 patent/WO2014123375A1/ko active Application Filing
- 2014-02-06 CN CN201480007732.1A patent/CN104968197A/zh active Pending
- 2014-02-06 JP JP2015555927A patent/JP2016513952A/ja active Pending
- 2014-02-06 EP EP14748526.2A patent/EP2954778A4/en not_active Withdrawn
- 2014-02-06 US US14/763,809 patent/US20150359207A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002369874A (ja) * | 2001-06-14 | 2002-12-24 | Terumo Corp | 止血材料 |
KR20070117589A (ko) * | 2005-02-15 | 2007-12-12 | 버지니아 커먼웰스 유니버시티 | 급성 지혈 및 급성 상처와 만성 궤양의 치료를 위한 광물기술 |
KR20080007380A (ko) * | 2005-04-25 | 2008-01-18 | 메사추세츠 인스티튜트 오브 테크놀로지 | 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및방법 |
JP2007181413A (ja) * | 2006-01-05 | 2007-07-19 | Fujifilm Corp | 血管壁障害モデル動物の作成方法 |
JP2011518592A (ja) * | 2008-04-25 | 2011-06-30 | メッドトレイド プロダクツ リミテッド | 止血材 |
Non-Patent Citations (3)
Title |
---|
BIJAN S ET AL., JOURNAL OF SURGICAL RESEARCH, vol. 106, 2002, pages 99 - 107 |
HASAN BILGILI ET AL., MED PRINC PRACT, vol. 18, 2009, pages 165 - 169 |
See also references of EP2954778A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20140100352A (ko) | 2014-08-14 |
EP2954778A4 (en) | 2016-07-27 |
KR101432276B1 (ko) | 2014-08-21 |
CN104968197A (zh) | 2015-10-07 |
EP2954778A1 (en) | 2015-12-16 |
JP2016513952A (ja) | 2016-05-19 |
US20150359207A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7012779B2 (ja) | 精製された両親媒性ペプチド組成物を用いた、外科的方法 | |
US5643596A (en) | Hemostatic patch | |
JP4903308B2 (ja) | コラーゲン止血繊維 | |
JP5675607B2 (ja) | 創傷被覆材 | |
US7560432B2 (en) | In situ method for treatment and repair of meniscal injuries | |
AU2352900A (en) | Collagen hemostatic foam | |
WO2013172504A1 (ko) | 연골조직 수복용 조성물과 제조방법 및 이의 사용방법 | |
JP7378486B2 (ja) | 医療用接着剤及びその調製方法、その用途 | |
CN112107723A (zh) | 医用水性黏胶及其使用方法 | |
BR112020015616B1 (pt) | Composição de biotinta para folha de regeneração de derme, método para fabricar folha de regeneração de derme customizada usando a mesma e folha de regeneração de derme customizada fabricada usando o método de fabricação | |
WO2014123375A1 (ko) | 총경동맥 또는 상시상 정맥동에 출혈이 유발된 지혈제 성능평가 동물모델 및 그 용도 | |
US20090054995A1 (en) | Planar implant | |
CN108884437A (zh) | 用于伤口愈合的干细胞 | |
TWI334878B (en) | Degradable dressing for wound healing appilcation | |
WO2020106074A1 (ko) | 창상치료용 약학조성물 | |
VerHulst | Comparison of conjunctival pedicle flap to corneal adhesion achieved by Tisseel® fibrin glue, ethyl cyanoacrylate adhesive, ReSure® hydrogel sealant, and conventional suturing with 8-0 VICRYL® suture | |
WO2020145456A1 (ko) | 드레싱재가 포함된 자궁경부 유착 방지 장치 | |
TWI791290B (zh) | 膠原蛋白顆粒於促進毛囊生成或血管生成之用途 | |
JP3620055B2 (ja) | 創傷治療剤 | |
Sanger et al. | Management of chronic osteomyelitis of the skull using vascularized omental transfer | |
RU2816662C1 (ru) | Способ консервативной мирингопластики с использованием "КОЛЛОСТ" мембраны | |
ALTMANN | HEALING OF FISTULAS OF THE HUMAN LABYRINTH: Histopathologic Studies | |
RU2257857C1 (ru) | Способ хирургического лечения заболеваний щитовидной железы | |
KR20220169912A (ko) | 콜레스테릭 액정 및 탄닌산을 포함하는 광학 활성 지혈제 조성물 및 이의 제조방법 | |
Hrynyk | Enhanced burn wound healing through controlled and sustained delivery of bioactive insulin from alginate sponge dressings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14748526 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14763809 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014748526 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014748526 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015555927 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |